Toronto Dominion Bank
TARA icon

Toronto Dominion Bank’s Protara Therapeutics TARA Stock Holding History

Toronto Dominion Bank’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,470
Closed -$65K – 2461
2026
Q1 		$65K Buy
+12,470
New +$73.8K ﹤0.01% 1739
2025
Q1 		– Sell
-2,088,937
Closed -$11M – 1691
2024
Q4 		$11M Buy
+2,088,937
New +$6.75M 0.02% 504

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Toronto Dominion Bank's TARA Position: Q2 2026 in Review

Toronto Dominion Bank sold out of Protara Therapeutics (TARA) in Q2 2026, closing a stake of 12,470 shares — an estimated $65K sold.

Toronto Dominion Bank first reported a position in TARA in Q4 2024 and held it in 2 quarters. The position peaked at $11M in Q4 2024. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Toronto Dominion Bank reported no remaining Protara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Toronto Dominion Bank sold 12,470 Protara Therapeutics shares in Q2 2026, an estimated $65K.
  • Toronto Dominion Bank first reported a position in Protara Therapeutics in Q4 2024 and held it in 2 quarters.
  • Toronto Dominion Bank's Protara Therapeutics position peaked at $11M in Q4 2024.
  • 119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Toronto Dominion Bank's 13F filing for Q2 2026, filed 14 Aug 2026.